Skip to contentV
Valion Bio, Inc.
V
VBIOValion Bio, Inc. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$180.00K$180.00Kderived−49.6% vs Q4 2023 Net Income-$1.48M-$1.48MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Valion Bio, Inc. · CIK 1787740 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived-$239,000N/M Operating Incomederived-$298,000N/M Operating Cash Flowderived-$1,365,000N/M Free Cash Flowderived-$1,365,000N/M Margins · derivedGross margin-132.8%−134.2 pt vs Q4 2023
Operating margin-165.6%+463.0 pt vs Q4 2023
Net margin-820.6%−192.3 pt vs Q4 2023
ended Dec 31, 2024 · filed Mar 21, 2025 · 80 d after period end